The Burden of Lung Cancer

Despite the use of aggressive surgery and combination chemotherapy, lung cancer remains difficult to control and is the biggest killer among cancers at 154,000 annual US deaths.

Lung cancer kills more people per year than prostate, pancreas, breast, and colon cancers combined.

Standard of Care

The pharmaceutical standard of care for lung cancer is primarily intravenous chemotherapy drugs, which have limited efficacy because of low drug concentration delivered to the lungs due to blood volume dilution.

Targeted Therapy

Quench Medical’s inhalation technology delivers the drug directly to tumor tissues in the lung thereby enhancing its efficacy due to increased local drug concentration in the lung, and decreased systemic toxicity due to decreased systemic drug levels in the circulation.

Increased Efficacy and Safety with Lower Doses

Our new method delivers the chemotherapeutic drug via dry powder inhalation to reach lung tumors directly, in lower doses, in order to maximize the effectiveness and safety of the cancer treatment.

Meet the Team


Bryce Beverlin II, Ph.D.

Founder & CEO

Linked In

Bryce Beverlin II founded Quench Medical to solve crucial problems in respiratory drug delivery for treating lung diseases. He is driven by a passion to help patients with lung diseases by developing the next-generation of highly performing treatments. Bryce is a physicist entrepreneur with 15 years of cross-functional R&D experience, postdoctoral commercialization training at the University of Minnesota's Medical Devices Center, biomedical engineering training, and a physics Ph.D. from the University of Minnesota. He has also developed technologies for Boston Scientific, Teijin Pharma, and the UMN.


Nancy Ness

Acting CFO

Linked In

Nancy Ness is a financial professional with extensive experience in biomedical company development who is an expert in shaping rounds of financing in addition to controllership and treasury duties. She has provided key financial and fundraising skills to over 40 early stage and commercial companies in Minnesota, Australia, Ireland, Pennsylvania, and California. Nancy has also served in various financial positions over the past 35 years, and for 20 years she has been focusing solely on consulting for the medical device and bio-pharma markets.


Peter Crosby

Board of Directors

Linked In

Peter Crosby has been Chief Executive Officer or Chairman of 7 medical device companies in four countries, including Mainstay Medical (IPO 2014), Cardiac Science (sold to Quinton Cardiology in 2006), Ischemia Technologies (sold to Inverness Medical in 2004), First Medical (sold to Sigma Diagnostics in 2000), NeoVision (sold to US Surgical in 1997), and Telectronics Pacing Systems (sold to St. Jude Medical in 1997). Peter is a specialist at bringing new medical devices to the global market, from concept to profitability. He has served as a key consultant in the fields of business strategy, intellectual property, research and development, capital markets, product launch and market development. Mr. Crosby’s specialties include: medical business development, financing & venture capital, mergers and acquisitions, product development, intellectual property, organizational development, marketing and sales. He has also served as expert witness in several lawsuits on IP, product liability, and commercialization.


John Foster

Board of Directors

Linked In

John Foster has more than 30 years of executive management experience and proven expertise in developing and bringing specialty pharmaceuticals and drug-device combination products to market. Mr. Foster is currently President and COO of Cerebral Therapeutics, a clinical-stage pharmaceutical company focused on treating neurological diseases. He was previously the founder and CEO of CNS Therapeutics, a specialty pharmaceutical company focused on developing and marketing intrathecal drugs for neurological disorders and pain. CNS was sold to Covidien/Mallinckrodt (October 2012). Mr. Foster has also served in key management positions at Restore Medical (which held an IPO in 2006 and was acquired by Medtronic in 2008), Advanced Respiratory, Medtronic’s Neuromodulation business, and Genentech. Currently, he serves as Chairman of Gillette Children’s Specialty Healthcare and serves on the Board of Directors for both SpineThera and NTF Therapeutics.


Quench Medical's aerosol platform technology is designed to deliver medicine into deep areas of the lung with unprecedented efficiency to greatly increase efficacy in treating pulmonary airway diseases.

Lung Cancer

Directly targeting lung tumors with inhaled therapeutic to significantly increase survival while minimizing systemic toxicity


Unprecedented efficient delivery of therapeutic to the deep undertreated small airways to reduce inflammation and costly exacerbations

Cystic Fibrosis

Deep penetration of therapeutic to treat infection and inflammation with high efficiency to increase healthspan


April 2021

  • Quench Medical's inhaled therapy for treating lung cancer is demonstrated to be highly effective in reducing tumor burden at half of the standard of care IV dose in a non-clinical lung cancer model.


January 2021

  • Quench Medical is accepted into the FDA CARES program at the National Cancer Institute.


September 2020

  • Quench Medical is awarded a Launch Minnesota SBIR Phase II Matching Grant from the Minnesota Department of Employment and Economic Development (DEED).


August 2020

  • National Cancer Institute awards Quench Medical a $400k Phase I SBIR grant for continued development of an inhaled therapy for treating lung cancer.

  • Quench Medical awarded a $2M Phase II SBIR grant from the NHLBI, continuing Phase I work awarded in March 2018. The grant will support further development of a proprietray inhaled therapy to target the small airways of patients with asthma.

  • Dr. Beverlin is accepted into the NHLBI Mentorship Program.

June 2020

  • Dr. Beverlin featured on Conscious Millionaire Podcast episode 1775. Listen here.


February 2020

  • Dr. Beverlin presents Quench Medical at the Colorado Life Sciences Night in Denver.


January 2020

  • Quench Medical is awarded a Launch Minnesota Innovation Grant from the Minnesota Department of Employment and Economic Development (DEED).


November 2019

  • Dr. Beverlin presents Quench Medical at the Colorado Capital Conference and takes home first prize as voted by the Rockies Venture Club investors in Golden, CO.


June 2019

  • Dr. Beverlin presents Quench Medical during the David vs. Goliath session at the Converge oncology conference in Philadelphia.


May 2019

  • Dr. Beverlin presents Quench Medical at the startup showcase at Drug Delivery West conference in San Francisco.


March 2019

  • SBIR Phase I efforts have been completed successfully and Quench Medical is applying for continued SBIR Phase II grant support as well as additional SBIR Phase I projects.


January 2019

  • Dr. Beverlin presents and meets with potential investors at JP Morgan conference in San Francisco.


December 2018

  • Poster presentation at Drug Delivery to the Lungs (DDL) conference in Edinburgh with researchers at VCU.


November 2018

  • Poster presentation at PharmSci360, an American Asociation of Pharmaceutical Scientists conference in Washington DC with researchers at VCU.


August 2018

  • Quench Medical joins the Medical Alley Association, a hub of healthcare innovation and resources, right here in Minnesota. Dr. Beverlin is featured and answers questions on their news blog. Read more here.


July 2018

  • Quench Medical's CEO Bryce Beverlin II has been invited to participate in the National Heart Lung and Blood Institute's Mentorship Program to connect Dr. Beverlin with veteran CEOs in the greater NHLBI community.


June 2018

  • Nancy Ness has joined Quench Medical as acting CFO! We are very excited to have Nancy's experience on board.

  • Quench Medical is featured in MHTA's entrepreneur profile news. Read more here.


May 2018

  • Dr. Beverlin presents Quench Medical's progress at the gBETA Medtech's event liveBETA, a celebration of gBETA Medtech's latest class of innovative startups focused on medical technology. 


April 2018

  • Quench Medical joins the inaugural cohort of gBETA Medtech accelerator, sponsored by Boston Scientific, Mayo Clinic, and the University of Minnesota. gBETA is a free, seven-week accelerator for early-stage companies with local roots, started by nationally ranked startup accelerator gener8tor. Read more at the Star Tribune

  • Dr. Beverlin attended the Respiratory Drug Delivery conference, sponsored by the VCU School of Pharmacy, where he met with key people in aerosol medicine development in academia, industry, and the FDA.


March 2018

  • A $225k SBIR seed grant from the National Institutes of Health is awarded to Quench Medical to develop a novel highly efficient dry powder aerosol formulation.


Subscribe to our mailing list

* indicates required

Email Us